Lung Cancer Biomarker Atlas

HomeBiomarkersTCGAPathwaysCompareMLmiRNAThesisProfile

TCGA Lung Cancer Cohort

Comprehensive overview of 1017 lung cancer samples across LUAD and LUSC subtypes

Total Samples

1017

Median Survival

47.8 mo

5-Year Survival

21.3%

Age Range

33-90

Median: 66

Cancer Subtypes

  • Lung Adenocarcinoma
  • Lung Squamous Cell Carcinoma
LUAD: Lung Adenocarcinoma585 (57.5%)
LUSC: Lung Squamous Cell Carcinoma432 (42.5%)

Stage Distribution

Stage IStage IIStage IIIStage IVUnknown015304560

Smoking Status

020406080CurrentFormerNeverUnknown

Top 10 Most Mutated Genes

1.TP53
52.3%
2.KRAS
32.4%
3.CDKN2A
22.1%
4.STK11
17.8%
5.KEAP1
15.6%
6.EGFR
18.7%
7.NFE2L2
14.2%
8.RB1
11.3%
9.PIK3CA
9.8%
10.BRAF
3.4%

Multi-omic Data Types

RNA-Seq (mRNA)

1017

20,531 features

miRNA-Seq

989

1,046 features

DNA Methylation

907

485,512 features

Copy Number Variation

1015

24,776 features

Somatic Mutations

984

Clinical Data

1017

LUAD vs LUSC Subtype Comparison

Mutation frequency differences between adenocarcinoma and squamous cell carcinoma

  • LUAD
  • LUSC
TP53EGFRKRASSTK11KEAP1PIK3CACDKN2APTENNFE2L2NF1SOX2FGFR10255075100Mutation Frequency (%)

LUAD

Typical mutations: EGFR, KRAS, STK11, TP53, ALK, ROS1
Smoking association: Weaker
Location: Peripheral lung
Median survival: 52.4 months
Targeted therapy: EGFR-TKIs, ALK inhibitors, KRAS G12C inhibitors, ROS1 inhibitors

LUSC

Typical mutations: TP53, CDKN2A, PIK3CA, NFE2L2, SOX2, FGFR1
Smoking association: Strong
Location: Central bronchi
Median survival: 41.2 months
Targeted therapy: FGFR inhibitors, Immunotherapy, Chemotherapy